Form 4: Nuvation Bio CPO Stacy Markel Reports Equity Holdings

Nuvation Bio's Chief People Officer, Stacy Markel, reported beneficial ownership of 32,591 Class A Common Stock shares and a new grant of 748,130 stock options.

Summary

• Stacy Markel, Chief People Officer of Nuvation Bio Inc. (NUVB), reported beneficial ownership of 32,591 shares of Class A Common Stock.
• The reported Class A Common Stock includes 3,000 shares acquired on November 19, 2025, under the Issuer's 2021 Employee Stock Purchase Plan.
• Markel was granted 748,130 stock options with an exercise price of $5.91 per share.
• The stock options were granted on February 27, 2026, and are set to expire on February 26, 2036.
• The options vest as to 25% on the one-year anniversary of the grant date (February 27, 2026), with the remaining portion vesting monthly over the subsequent 36 months, contingent on continuous service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating continued executive commitment and alignment of interests through equity incentives, which is generally favorable for long-term stability and performance.

Positives

• The Chief People Officer's participation in the Employee Stock Purchase Plan indicates personal investment and confidence in the company.
• A significant grant of 748,130 stock options aligns the executive's long-term incentives with shareholder value creation.

Future Outlook

The long-term vesting schedule for the stock options indicates a strategic move to retain the Chief People Officer and align their performance incentives with the company's future growth and success over several years.

Industry Context

StockSavvy.ai notes that significant option grants to C-suite executives like the Chief People Officer are standard practice for aligning executive incentives with long-term shareholder value, particularly in biotech companies like Nuvation Bio, where talent retention and motivation are crucial for navigating complex R&D and market challenges.

Comparison to Industry Standards

• StockSavvy.ai observes that the option grant size and vesting schedule are typical for executive compensation packages in the biotechnology sector, comparable to grants seen at companies like Moderna or BioNTech for similar executive roles, aiming to incentivize long-term commitment and performance.

Stakeholder Impact

• Shareholders benefit from the alignment of executive incentives with long-term company performance, potentially leading to increased shareholder value.
• The Chief People Officer benefits from equity compensation, providing a direct financial stake in the company's success and fostering retention.

Next Steps

• Vesting of stock options will occur on a schedule, with 25% vesting on February 27, 2027, and the remainder vesting monthly over the subsequent 36 months, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a key executive, Stacy Markel, including an option grant and shares acquired through an ESPP. While it demonstrates continued executive alignment and commitment, it does not present new information that would fundamentally alter the investment thesis for Nuvation Bio Inc. Therefore, a 'hold' recommendation is appropriate as it confirms ongoing executive incentives without providing a catalyst for a 'buy' or 'sell' decision.

Keywords

Nuvation Bio, NUVB, Stacy Markel, Form 4, insider transaction, stock options, equity ownership, Chief People Officer, employee stock purchase plan